Ascendis Pharma A (ASND) Revenue (2014 - 2026)

Ascendis Pharma A has reported Revenue for 13 years, with the latest figure at $288.7 million in Q1 2026.

• Quarterly Revenue rose 171.87% year-over-year to $288.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 122.73% YoY) and the FY2025 annual result came in at $838.3 million, up 93.32% from the prior year.
• Revenue fell to $288.7 million in Q1 2026 per ASND's latest filing, from $484.8 million in the prior quarter.
• Over five years, Revenue peaked at $484.8 million in Q4 2025 and troughed at $6.6 million in Q2 2022.
• A 5-year average of $139.1 million and a median of $63.5 million in 2024 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2023: Revenue slumped 76.29% in 2022, then soared 1294.35% in 2023.
• Over 5 years, Revenue stood at $23.4 million in 2022, then soared by 1294.35% to $325.7 million in 2023, then grew by 1.7% to $331.2 million in 2024, then surged by 46.35% to $484.8 million in 2025, then sank by 40.44% to $288.7 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $288.7 million, $484.8 million, and $249.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.